Boehringer-Ingelheim pill Hernexeos was awarded accelerated FDA approval for advanced cases of non-small cell lung cancer with HER2 mutations. But Bayer is on its heels with an oral small molecule currently under FDA review in the same indication.
February has seen a slew of executive hires, exits and layoffs across the healthcare industry. For example, health tech companies like Cadence and Bamboo Health hired new C-suite leaders, and providers like Mass General Brigham and Corewell Health announced rounds of job cuts.
In this episode hear how improving benefit verification, prior authorizations, and patient affordability with smart integrations and real-time eligibility can streamline healthcare workflows.
Boehringer’s adalimumab-adbm is being offered on GoodRx’s platform for $550 per two-pack, a 92% discount from the Humira list price, according to the companies.
The first FDA-approved MASH drug doesn’t treat patients with liver cirrhosis. A new Boehringer Ingelheim/Ochre Bio collaboration is researching regenerative medicines that could treat patients in this most advanced stage of the fatty liver disease.
Sosei Heptares’ schizophrenia drug candidate addresses a novel, difficult-to-drug target for neurological disorders. Boehringer Ingelheim can exercise its option on the small molecule following a Phase 1 test expected to yield data in 2025.
Preliminary Phase 2 results show 83% of those treated with Boehringer Ingelheim and Zealand Pharma drug survodutide met the main goal of improvement in the fatty liver disease MASH. Boehringer contends this drug has best-in-class potential in a competitive field that includes an Eli Lilly drug that recently posted positive Phase 2 results.
There are a number of criteria for selecting the best autism therapy centers. Parents choosing a facility or professionals seeking to improve their offerings should consider certain standards to ensure the right fit.
Boehringer Ingelheim has shown biosimilar manufacturers the way to win interchangeability with the world’s highest-grossing drug — but the company’s Cyltezo won't come out until July 2023. Will future Humira competitors have better luck winning an earlier launch date?
According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. Two reports list 18 drugs as losing patent protection or exclusivity, though not all drugs listed here will necessarily face generic or biosimilar competition in 2020.
The German drugmaker announced a partnership with Enleofen to develop the company's suite of preclinical antibodies targeting IL-11 in diseases like NASH.
BI said it would continue to develop the drug, BI 1467335, in other diseases and remain committed to NASH overall. Shares of the Australian company from which it licensed the drug, Pharmaxis, fell more than 40%.
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
The two organizations are placing particular emphasis on lung and gastrointestinal cancers, as well as drug targets like KRAS mutations.
The deal includes an upfront payment and up to 100 million euros in milestones, equaling $364.5 million. Amal's lead candidate is a vaccine for colorectal cancer expected to enter the clinic later this month.
A panel discussion at the upcoming MedCity INVEST meeting in Chicago will look at real-world applications of blockchain technology in healthcare and biopharma.
At the ongoing HIMSS conference in Orlando, Florida, the companies' Canadian divisions said their partnership would mark the technology's first use in clinical trials in Canada.
Market forecast rosy, though market in United States remains young.